239 related articles for article (PubMed ID: 34355696)
1. Expanding the MECP2 network using comparative genomics reveals potential therapeutic targets for Rett syndrome.
Unterman I; Bloch I; Cazacu S; Kazimirsky G; Ben-Zeev B; Berman BP; Brodie C; Tabach Y
Elife; 2021 Aug; 10():. PubMed ID: 34355696
[TBL] [Abstract][Full Text] [Related]
2. Proteomic and transcriptional changes associated with MeCP2 dysfunction reveal nodes for therapeutic intervention in Rett syndrome.
Marballi K; MacDonald JL
Neurochem Int; 2021 Sep; 148():105076. PubMed ID: 34048843
[TBL] [Abstract][Full Text] [Related]
3. Deciphering Rett syndrome with mouse genetics, epigenomics, and human neurons.
Tao J; Wu H; Sun YE
Int Rev Neurobiol; 2009; 89():147-60. PubMed ID: 19900619
[TBL] [Abstract][Full Text] [Related]
4. MeCP2 and Rett syndrome: reversibility and potential avenues for therapy.
Gadalla KK; Bailey ME; Cobb SR
Biochem J; 2011 Oct; 439(1):1-14. PubMed ID: 21916843
[TBL] [Abstract][Full Text] [Related]
5. Exploring the possible link between MeCP2 and oxidative stress in Rett syndrome.
Filosa S; Pecorelli A; D'Esposito M; Valacchi G; Hajek J
Free Radic Biol Med; 2015 Nov; 88(Pt A):81-90. PubMed ID: 25960047
[TBL] [Abstract][Full Text] [Related]
6. Role of DNA Methyl-CpG-Binding Protein MeCP2 in Rett Syndrome Pathobiology and Mechanism of Disease.
Pejhan S; Rastegar M
Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33429932
[TBL] [Abstract][Full Text] [Related]
7. Recent endeavors in MECP2 gene transfer for gene therapy of Rett syndrome.
Sinnett SE; Gray SJ
Discov Med; 2017 Oct; 24(132):153-159. PubMed ID: 29272692
[TBL] [Abstract][Full Text] [Related]
8. MECP2 mutations and clinical correlations in Greek children with Rett syndrome and associated neurodevelopmental disorders.
Psoni S; Sofocleous C; Traeger-Synodinos J; Kitsiou-Tzeli S; Kanavakis E; Fryssira-Kanioura H
Brain Dev; 2012 Jun; 34(6):487-95. PubMed ID: 21982064
[TBL] [Abstract][Full Text] [Related]
9. Proteomic analysis of the Rett syndrome experimental model mecp2
Cortelazzo A; Pietri T; De Felice C; Leoncini S; Guerranti R; Signorini C; Timperio AM; Zolla L; Ciccoli L; Hayek J
J Proteomics; 2017 Feb; 154():128-133. PubMed ID: 28062374
[TBL] [Abstract][Full Text] [Related]
10. Reduction of aberrant NF-κB signalling ameliorates Rett syndrome phenotypes in Mecp2-null mice.
Kishi N; MacDonald JL; Ye J; Molyneaux BJ; Azim E; Macklis JD
Nat Commun; 2016 Jan; 7():10520. PubMed ID: 26821816
[TBL] [Abstract][Full Text] [Related]
11. Methyl-CpG binding protein 2 gene (MECP2) variations in Japanese patients with Rett syndrome: pathological mutations and polymorphisms.
Fukuda T; Yamashita Y; Nagamitsu S; Miyamoto K; Jin JJ; Ohmori I; Ohtsuka Y; Kuwajima K; Endo S; Iwai T; Yamagata H; Tabara Y; Miki T; Matsuishi T; Kondo I
Brain Dev; 2005 Apr; 27(3):211-7. PubMed ID: 15737703
[TBL] [Abstract][Full Text] [Related]
12. Progressive Changes in a Distributed Neural Circuit Underlie Breathing Abnormalities in Mice Lacking MeCP2.
Huang TW; Kochukov MY; Ward CS; Merritt J; Thomas K; Nguyen T; Arenkiel BR; Neul JL
J Neurosci; 2016 May; 36(20):5572-86. PubMed ID: 27194336
[TBL] [Abstract][Full Text] [Related]
13. Rett syndrome: methyl-CpG-binding protein 2 mutations and phenotype-genotype correlations.
Amir RE; Zoghbi HY
Am J Med Genet; 2000; 97(2):147-52. PubMed ID: 11180222
[TBL] [Abstract][Full Text] [Related]
14. Rett syndrome: a neurological disorder with metabolic components.
Kyle SM; Vashi N; Justice MJ
Open Biol; 2018 Feb; 8(2):. PubMed ID: 29445033
[TBL] [Abstract][Full Text] [Related]
15. A codon-optimized Mecp2 transgene corrects breathing deficits and improves survival in a mouse model of Rett syndrome.
Matagne V; Ehinger Y; Saidi L; Borges-Correia A; Barkats M; Bartoli M; Villard L; Roux JC
Neurobiol Dis; 2017 Mar; 99():1-11. PubMed ID: 27974239
[TBL] [Abstract][Full Text] [Related]
16. Spectrum of MECP2 mutations in Rett syndrome.
Bienvenu T; Villard L; De Roux N; Bourdon V; Fontes M; Beldjord C; Tardieu M; Jonveaux P; Chelly J;
Genet Test; 2002; 6(1):1-6. PubMed ID: 12180070
[TBL] [Abstract][Full Text] [Related]
17. Quantitative localization of heterogeneous methyl-CpG-binding protein 2 (MeCP2) expression phenotypes in normal and Rett syndrome brain by laser scanning cytometry.
LaSalle JM; Goldstine J; Balmer D; Greco CM
Hum Mol Genet; 2001 Aug; 10(17):1729-40. PubMed ID: 11532982
[TBL] [Abstract][Full Text] [Related]
18. The impact of MECP2 mutations in the expression patterns of Rett syndrome patients.
Ballestar E; Ropero S; Alaminos M; Armstrong J; Setien F; Agrelo R; Fraga MF; Herranz M; Avila S; Pineda M; Monros E; Esteller M
Hum Genet; 2005 Jan; 116(1-2):91-104. PubMed ID: 15549394
[TBL] [Abstract][Full Text] [Related]
19. RNA sequencing and proteomics approaches reveal novel deficits in the cortex of
Pacheco NL; Heaven MR; Holt LM; Crossman DK; Boggio KJ; Shaffer SA; Flint DL; Olsen ML
Mol Autism; 2017; 8():56. PubMed ID: 29090078
[TBL] [Abstract][Full Text] [Related]
20. MECP2 mutations in Czech patients with Rett syndrome and Rett-like phenotypes: novel mutations, genotype-phenotype correlations and validation of high-resolution melting analysis for mutation scanning.
Zahorakova D; Lelkova P; Gregor V; Magner M; Zeman J; Martasek P
J Hum Genet; 2016 Jul; 61(7):617-25. PubMed ID: 26984561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
